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A B S T R A C T
Zinc oxide (ZnO) based nanostructures owing unique physical properties – high photoluminescence, bio-
compatibility and other characteristics, therefore, they attract attention as building blocks suitable for biosensor
development. In this research as a target we have used human leukemic cell line IM9 (IM9). IM9 was derived
from the patient with a multiple myeloma and expressed cluster of differentiation proteins СD19 on the surface
of 85–95% here investigated cancer cells. As a control sample healthy human's peripheral blood mononuclear
cells (PBMC) were used and the expression of CD19 protein was found only in 5–9% of these cells. Two types of
antibodies labeled by fluorescein isothiocyanate (FITC) were used for the labeling of human leukemic cells:
FITC-conjugated mouse antibodies against Human CD19 protein (anti-CD19-FITC*) and FITC-conjugated mouse
antibodies against Human IgG1 protein (anti-IgG1-FITC*). In order to demonstrate the applicability of zinc oxide
nanorods (ZnO-NRs) based platforms three types of ZnO-NRs-based structures were investigated: (i) ZnO-NRs
modified by anti-CD19-FITC*; (ii) ZnO-NRs modified by IM9 cells, which were pre-incubated with anti-CD19-
FITC*; (iii) ZnO-NRs modified by PBMC cells, which were pre-incubated with anti-CD19-FITC*. It was de-
monstrated that IM9 cells after specific interaction with anti-CD19-FITC* bind to ZnO-NRs (ZnO-NRs/
IM9+anti-CD19-FITC*) and photoluminescence based signal significantly increase in comparison with that
observed in control samples, which contained PBMC cells incubated with anti-CD19-FITC* (ZnO-NRs/
PBMC+anti-CD19-FITC*). The photoluminescence results are in good correlation with the data obtained by flow
cytometry. This study illustrate that ZnO-NRs exhibit a photoluminescence signal suitable for the determination
of anti-CD19-FITC* labeled IM9 cell line at concentrations – from 10 till 500 cells adsorbed per 1mm2 of ZnO-
NRs platform.
1. Introduction
Chronic lymphocytic leukemia (CLL) is a human monoclonal dis-
order characterized by a progressive accumulation of functionally in-
competent lymphocytes (B cells). The leukemia cells are produced in
the bone marrow but then go into the blood. In time, the cells can
spread to other parts of the body, including the lymph nodes, liver, and
spleen [1,2]. With more than 15,000 cases recognized annually, CLL is
the most common form of leukemia diagnosed in adults in Western
countries, resulting in almost 5000 cancer-related deaths yearly in the
United States [3]. In CLL, the leukemia cells often build up slowly over
time, and many people don't have any symptoms for at least a few years
[2]. Despite the fact that the modern approaches of therapy prolong the
remission in CLL patients, to date, this disease is considered an incur-
able one [4].
Nowadays, the diagnosis of this disease includes: 1) analysis of the
B-cells amount in human peripheral blood, 2) analysis of blood smears
for determination of tumor cells morphology, 3) cytogenetic analysis to
detect the presence of the specific DNA sequences on chromosomes, 4)
bone marrow aspiration and biopsy and 5) the peripheral lymphocytes
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immunophenotyping [2,3]. Lymphocytes immunophenotyping using
flow cytometry is mandatory for the confirmation of diagnosis. Such a
high-sensitivity method as flow cytometry can detect one cancer cell in
the presence of 10,000 normal leukocytes [5]. Hence, recently very
actual task is to develop a new, simple leukemia diagnostic tool of their
use compared to flow cytometry. A suitable solution of here posed
problem can be a device based on biosensor technology [6], in parti-
cular immunosensors [7,8]. The advantages of the immunosensors are
simple instrumentation, high sensitivity and selectivity, and compat-
ibility with miniaturized and portable systems [9].
Zinc oxide (ZnO) is an important wide band gap semiconductor
material having a great potential of application in catalysis, sensing and
nano-device development based on its unique physical properties.
Nanostructured ZnO not only possesses high surface area, good bio-
compatibility and chemical stability being non-toxic, but it also shows
biomimetic and high electron communication features important for
potential applications in biosensing [6]. The surface of ZnO nanoma-
terials has chemical functionality required for covalent derivatization to
allow linking of specific biomolecules and to increase specificity of
biomolecular interaction [10].
However, the application of ZnO in biological or clinical testing
schemes have remained largely unexplored, so far even though many
biological assay systems rely on optical detection techniques.
Photoluminescence is one of the most widely used detection mechan-
isms in many fields such as biology, biophysics, biochemistry, geno-
mics, proteomics, drug discovery, disease diagnostics and environ-
mental analysis. Major challenges associated with such fluorescence
techniques include enhancing detection sensitivity and increasing
signal-to-noise ratio. Novel methods that overcome current drawbacks
and enable rapid, facile, high-throughput, ultrasensitive, and specific
optical detection are in great demand [6].
Many efforts have been recently made to construct ZnO-based bio-
sensors with high performance [11,12]. Corso et al. [13] developed an
effective antibody immobilization technique that imparts sensitivity
and specificity to the ZnO-based devices. Moreover, using ZnO-based
quantum dots as electrochemical and fluorescent labels, a sandwich
type sensitive immunoassay was developed to detect carbohydrate an-
tigen 19-9, which is a preferred label for pancreatic [14]. Viter et al.
have previously developed system for the detection of Salmonella and
Ochratoxin A by ZnO-nanorods based photoluminescence system
[15,16]. It was found that the immobilization of bioselective layers,
which are based on anti-Salmonella or anti-Ochratoxin A antibodies,
immobilized onto ZnO-nanorods lead to an increase of the intensity of
photoluminescence and after interaction with Salmonella and Ochra-
toxin A antigens the intensity of PL is decreasing proportionally to an-
tigens concentration.
Previously we also have reported on a portable analytic system for
cancer cell detection [17]. In this work colloidal solution of ZnO-na-
norods were used for the visualization of target cancer cells (adherent
carcinoma cells) attached to a glass slide surface.
In the present work we have demonstrated applicability of ZnO-
nanorod-based layer for the development of immunosensing platform
suitable for the detection cancer (B-lymphoblastoid cell line IM9) cells.
2. Materials and methods
2.1. Materials
Blood from healthy donors was obtained from the Republic
Research & Production Center for Transfusiology and Medical
Biotechnologies (Minsk, Belarus). Cell line IM9 (ATCC CCL 159) was
obtained from Institute of cytology of RAN (St. Petersburg, Russia).
All the chemicals in the experiment were used without further
purification. Histopaque-1077, trypan blue, RPMI-1640 medium, fetal
bovine serum, L-glutamine, penicillin, streptomycin, L-butanol,
ethanol, paraformaldehyde were purchased from (Sigma-Aldrich,
Germany). Fluorescein isothiocyanate (FITC)-conjugated mouse against
human CD19 (anti-CD19-FITC*) monoclonal antibody (Mab), FITC*-
conjugated mouse against Human IgG1 polyclonal antibody (anti-IgG1-
FITC*) were purchased from (Beckman Coulter, USA).
2.2. Cells and cell culture
PBMC cells were isolated from heparinized peripheral blood from
healthy donors by centrifugation on a Histopaque density gradient
(density: 1.077 g/ml), washed twice in 10mM Phosphate buffer saline
pH 7.2 (PBS) at 300×g for 30min and re-suspended in culture medium
(RPMI-1640 with 10% FBS) at a final density of 1×106 cells/ml. Cell
viability was determined by Trypan blue dye exclusion. The purified
PBMC were used for experimental analysis within 1 day from their
isolation.
Human lymphoblastoid cell line IM9 (IM9) was cultured in a com-
plete RPMI-1640 medium supplemented with 10% (v/v) heat-in-
activated fetal bovine serum (FBS) (56 °C for 60min), L-glutamine
(2mmol/L), penicillin (100 U/ml), streptomycin (100 µg/ml) at 37 °C
in a 5% CO2: 95% air humidified atmosphere. Only exponentially
growing cultures of cells were used in the experiments.
2.3. Flow cytometry analysis of cells surface marker
IM9 and PBMC cells were analyzed for B-cell subpopulations by
flow cytometry. Cell suspensions (1×106 cells/ml) were stained for
surface marker expression using anti-CD19-FITC* and anti-IgG1-FITC*
for 1 h at room temperature in a dark and twice washed with PBS
300×g for 10min. Cells were analyzed using FACSCanto II BD
Biosciences (BD Biosciences, San Jose, USA). For analysis, forward and
side scatter gates were set to include viable cells and to exclude dead
cells and debris. A minimum of 20000 lymphocyte-gated events was
acquired on a flow cytometry, with data analyzed by FCSExpress
Version 3 Research Edition De Novo software for enhanced acquisition
analysis from De Novo (Glendale, USA).
2.4. The synthesis of ZnO-nanorods
ZnO-nanorods (ZnO-NRs) were obtained by the gaseous-disperse
synthesis (GDS) [18]. The method comprises specially organized two-
phase flames of dust clouds of the corresponding metals (pure metals,
mechanical mixtures or alloys of different metals). The final product is
obtained as a result of condensation of gaseous phase products of metal
burning in the oxidizing atmosphere. For further use of ZnO-NRs, they
were dispersed in 99,8% 1-butanol in order to prepare 10mg/ml al-
cohol solution and then ultrasonically treated for 30min, 44 kHz.
2.5. The preparation of ZnO-nanorod-based platform
18mm square glass cover slips and 1–10mg/ml zinc oxide nanorods
stock solutions were used for the preparation of platforms. Glass sub-
strate was cleaned in 70% ethanol and deionized water and treated
oxygen plasma using Plasma Cleaner from Harrick Plasma (Ithaca,
USA). After that 10 µl of ZnO-NRs stock solution was dropped on glass
substrate and dried at room temperature for 12 h. The ZnO-NRs formed
a layer on the substrate (glass/ZnO-NRs), which was further annealed at
300 °C in air atmosphere for 2 h. In this way glass/ZnO-NRs platform
was prepared for the modification by FITC*-labeled antibodies and
cells.
2.6. Modification of glass/ZnO-NRs by antibodies and antibody-pre-treated
cells
Three types of ZnO-NRs-based samples were prepared for in-
vestigations:
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1) Anti-CD19-FITC* and anti-IgG1-FITC* antibodies were adsorbed on
the glass/ZnO-NRs substrate in order to form glass/ZnO-NRs/anti-
CD19-FITC* structures and glass/ZnO-NRs/anti-IgG1-FITC*
structures. For this 4 µl of anti-CD19-FITC* and anti-IgG1-
FITC* (final concentration was 1.25–25.0 µg/ml) was dropped on
ZnO nanorod modified substrates and maintained for 12 h at 4 °C.
Then antibodies were fixed by 1% solution of paraformaldehyde in
PBS, pH 7.2.
2) Human leukemia cells (IM9) were incubated with anti-CD19-
FITC* or anti-IgG1-FITC* antibody (1 h at room temperature) and
then the solution of FITC* modified IM9 cells (IM9+anti-CD19-
FITC* and IM9+anti-IgG1-FITC*, respectively) was deposited on
the glass/ZnO-NRs substrates and incubated for 12 h at 4 °C in order
to form glass/ZnO-NRs/IM9+anti-CD19-FITC* or glass/ZnO-NRs/
IM9+anti-IgG1-FITC* structures, respectively. These samples were
washed with PBS, pH 7.2, in order to remove unbounded IM9 and
IM9+anti-IgG1-FITC* or IM9+anti-IgG1-FITC*cells from glass/
ZnO-NRs surface. After this cells were fixed by 4% solution of par-
aformaldehyde in PBS pH 7.2.
3) The same procedures were performed with ‘control’ samples of
healthy human's peripheral blood mononuclear cells (PBMC). PBMC
cells were incubated with both types of antibodies (with anti-CD19-
FITC* or anti-IgG1-FITC* antibody) and then FITC*modified PBMC
cells (PBMC+anti-CD19-FITC* and PBMC+anti-IgG1-FITC*, re-
spectively) was deposited on the glass/ZnO-NRs substrates and in-
cubated for 12 h at 4 °C in order to form glass/ZnO-NRs/
PBMC+anti-CD19-FITC* or glass/ZnO-NRs/PBMC+anti-IgG1-
FITC* structures, respectively. These samples were washed with
PBS, pH 7.2, in order to remove unbounded PBMC and PBMC+anti-
IgG1-FITC* or PBMC+anti-IgG1-FITC* cells from glass/ZnO-NRs
surface. After this cells were fixed by 4% solution of paraf-
ormaldehyde in PBS pH 7.2.
Further characterization of structural and optical properties was
performed for the next structures: glass/ZnO-NRs, glass/ZnO-NRs/anti-
CD19-FITC* , glass/ZnO-NRs/anti-IgG1-FITC* , glass/ZnO-NRs/
PBMC+anti-CD19-FITC* , glass/ZnO-NRs/IM9+anti-CD19-FITC* and
glass/ZnO-NRs/IM9+anti-IgG1-FITC*.
2.7. Imaging by scanning electron microscopy
The morphology of the obtained samples (bare ZnO nanorods sub-
strates as well as ZnO substrates modified with monoclonal antibody
and cells) was studied by scanning electron microscopy (SEM). Cells
were prepared for SEM imaging by fixation on the substrate with 4%
PFA buffered in PBS pH 7.2. Scanning electron microscopy imaging was
performed by electron microscope S-4800 FE-SEM from Hitachi
(Krefeld, Germany). Images of samples were taken at 1.0–35.0 k×
magnifications with acceleration voltages ranging 1.0–5.0 kV.
2.8. Photoluminescence analysis of ZnO-NRs based structures
Photoluminescence (PL) spectra of glass/ZnO-NRs-based structures
at room temperature were registered and they were similar to that re-
ported by Viter et al. [7,15,19,20]. PL was excited using UV solid state
laser LGI-21 (output power 0.4mW, with 337 nm excitation wave-
length). The emission spectra were recorded at room temperature in the
range of 370–800 nm using spectrometer HR2000+(Ocean Optics).
2.9. Raman microscopy analysis
The bare glass/ZnO-NRs as well as glass/ZnO-NRs/anti-CD19-FITC*
and that structures treated by target-cells (glass/ZnO-NRs/IM9+anti-
CD19-FITC*) were investigated using Raman spectroscopy (RS). Raman
spectroscopy experiments were performed using combined Raman and
SNOM microscope Alpha 300 RS (WiTec, Germany), equipped with
532 nm excitation laser source. Laser light filtered by a plasma filter
was focused onto the sample with 100x objective. The scattered Raman
signal was collected with the same objective in the backscattering
geometry and detected by CCD detector cooled down to −61 °C.
3. Results and discussion
3.1. Microstructure and photoluminescence properties of bare ZnO
nanorods
Analysis of the literature showed that ZnO-NRs have attracted at-
tention for biosensing applications due to their chemical stability, high
specific surface area, and electrochemical activity [6,21,22]. Based on
the evidence that the use of ZnO-NRs-based platforms may facilitate a
sensitive fluorescence detection of biomolecules [23], the ZnO-NRs-
based platforms have been evaluated for enhanced fluorescence assays
involving component of biological systems such as DNA and proteins
[23,24]. In more complex biological assays of multi-component sys-
tems, ZnO-NRs-based platforms have demonstrated their impact on the
sensitive fluorescence detection of cancer and kidney disease bio-
markers [25]. Therefore, the first stage of our work was to create and to
analyze/characterize ZnO-NRs-based platforms suitable for the appli-
cation in immunosensors.
The microstructure of obtained ZnO-NRs deposited on a glass sub-
strate was characterized by SEM. Fig. 1 displays typical SEM images of
ZnO-NRs in a stripe array sample. ZnO-NRs prepared according to our
method are uniform in diameter, length, and crystalline structure. The
average diameter of the ZnO-NRs was about 50 nm and the length of
ZnO-NRs could reach up to 500 nm.
The room temperature photoluminescence (RT-PL) spectrum of bare
glass/ZnO-NRs substrate is shown in Fig. 2. The registered PL spectrum
has two peaks: (i) a narrow and intense peak, which is centered at
380 nm and (ii) a wide non-symmetric peak, which is centered at
520 nm. The photoluminescent properties of ZnO-based nanostructures
usually exhibit near-band-edge (NBE) emissions and the broad deep-
level emission (DLE) or visible luminescence due to exciton transitions
and defect emission, respectively [26].
The structural, optical and electrical properties of ZnO nanos-
tructures are strongly interrelated [26,27]. Usually the NBE/DLE ratio
of ZnO nanostructures increases with the optimization of composition
stoichiometry [26]. However the light emission properties of ZnO na-
nostructures are affected by surface layer depletion in case of a high
ratio of surface to volume [27]. The NBE and DLE intensities are re-
duced as photo-generated electrons are captured on surface increasing
the band bending and excitons dissociate in the electrical field, induced
by the surface charge [15,26]. Due to the expected sensing mechanism
in present work we have focused on the NBE emission peak intensity,
which in this particular case is the most informative analytical signal.
Fig. 1. SEM images of ZnO-NRs deposited on glass (glass/ZnO-NRs).
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Prior to the evaluation of glass/ZnO-NRs-based platforms the op-
timal ZnO-NRs concentration was determined. In order to achieve this
goal the following ZnO-NRs concentrations were tested: 1mg/ml;
2.5 mg/ml; 5mg/ml; 10mg/ml.
The NBE part of the PL spectra of ZnO-NRs, deposited on glass
substrates from solutions with different concentrations is shown in
Fig. 3. The PL intensity of ZnO-NRs non-significantly increases with an
enhancement of the concentration of ZnO-NRs in solution. Also, no
linear dependence between PL intensity and concentrations of ZnO-NRs
in solution is observed. Moreover, the PL intensity of ZnO-NRs at
concentrations of 5 and 10mg/ml was almost the same, it indicate the
achievement of a saturation of PL signal at ZnO-NRs concentrations,
which are exceeding 5mg/ml.
SEM microstructure studies of obtained ZnO-NRs are shown in SEM
images (Fig. 4) ZnO-NRs at concentration of 1mg/ml formed a mono-
layer on glass substrate whereas when level of ZnO-NRs was more than
1mg/ml the deposited ZnO-NRs overlapped and formed conglomerates.
It indicates about the maximum degree of packing of ZnO-NRs in cur-
rent volume and surface area occupied by them after the annealing.
Increase in PL intensity in the case of 2.5 mg/ml ZnO-NRs compared
with 1mg/ml indicates about the increase of ZnO-NRs packing degree
in present surface area, however, this leads to the formation of not
uniform layer. Thus, 1 mg/ml ZnO-NRs deposited on a glass substrate is
an optimal concentration for the further preparation of ZnO-NRs-based
platform.
3.2. The determination of immuno-phenotype of donor's lymphocytes and
IM9 cell line by flow cytometry using anti-CD19-FITC*
As mentioned in the introduction part, B-CLL is a disease char-
acterized by a pathologic accumulation of the immunologically
incompetent B-lymphocytes in the bone marrow, lymph nodes, liver,
spleen and peripheral blood [1]. In normal peripheral blood, CD19
protein or B-lymphocytic antigen CD19 is expressed on the cell mem-
brane at 5–20% of total lymphocytes population [1]. To investigate the
expression of CD19 protein on B-leucosis lymphocytes, the human B-
lymphoblastoid cell line IM9 was studied, because it is known that this
cell line has CD19 antigen expression.
Figs. 5 and 6 correspond to representative dot plots distribution
profiles of donor's peripheral mononuclear cells and human B-lym-
phoblastoid cell line IM9 during the evaluation of CD19 marker ex-
pression on their surface. Figs. 5A and 6A show donor's lymphocytes
and B lymphoblast cells gates, respectively, sorted according to forward
side scatter (FSC) and side scatter (SSC). Also the auto-fluorescence of
targeted cells (Figs. 5B, 6B) and a sample of cells that has been stained
with anti-CD19-FITC* (Figs. 5D and 6D) are represented. The overall
positive expression rates of CD19 marker (CD19 positive cells) in do-
nor's lymphocytes is 4.62% (Fig. 5D) and in human B-lymphoblastoid
cell line IM9 is 95.02% (Fig. 6D).
It is known that antibodies can bind to cells in a specific manner,
where the Fab (fragment antigen-binding) fragment of the antibody
binds to a high-affinity specific target or the Fc (fragment crystallizable)
fragment of the antibody binds to the Fc receptors on the surface of
cells. However, they can also bind in a nonspecific manner, where the
Fab fragment binds to a low affinity, non-specific target. Hence, in
order to increase selectivity of cell determination, at the same time we
have used isotype control for anti-CD19 monoclonal antibody. IgG1 in
our case is a negative control designed to measure the level of non-
specific background signal caused by anti-CD19 monoclonal antibody,
based upon the tissue type of the sample. This background signal is the
result of non-specific immunoglobulin's binding to Fc receptors present
on the B-cell surface. Figs. 5C and 6C show samples of investigated cells
that have been labeled with anti-IgG1-FITC*. In this case the overall
positive expression rates of IgG1 (a nonspecific binding) in donor's
lymphocytes is 0.23% (Fig. 5C) and in the human B-lymphoblastoid cell
line is 0.32% (Fig. 6C).
3.3. The evaluation of photoluminescent properties of ZnO-nanorods after
the adsorption of monoclonal antibodies
Optical properties of glass/ZnO-NRs platforms after the modifica-
tion with anti-CD19-FITC* monoclonal antibody (glass/ZnO-NRs/anti-
CD19-FITC*) in order to find conditions for further determination of
photoluminescence-based analytical signal have been investigated.
FITC conjugated anti-human CD19 monoclonal antibody (anti-CD19-
FITC*) were applied. It is known that FITC has emission bands in visible
range from 480 nm to 640 nm, but NBE part of ZnO-NRs spectrum does
not exhibit emission in this spectrum range [15]. This enables to use the
same monoclonal antibody (anti-CD19-FITC*) for an im-
munophenotypic analysis of cells and for subsequent analysis by pho-
toluminescence method. For the modification of glass/ZnO-NRs plat-
forms 1.25 µg/ml; 2.5 µg/ml; 6.25 µg/ml; 12.5 µg/ml and 25.0 µg/ml
concentrations of monoclonal antibody were used.
Photoluminescence based evaluation reveals that anti-CD19-
FITC*modified glass/ZnO-NRs (glass/ZnO-NRs/anti-CD19-FITC*) leads
to an increase in PL intensity and this increase of PL signal in the range
of monoclonal antibody concentration from 1.25 till 6.25 µg/ml
(Fig. 7). In a case of formation of glass/ZnO-NRs/anti-CD19-FITC*
structure using 1.25 µg/ml of anti-CD19-FITC* solution the PL intensity
of ZnO-NRs was about 15,500 a.u.; using 2.5 µg/ml – 17,700 a.u.; and
using 6.25 µg/ml – 21,500 a.u., while in glass/ZnO-NRs/anti-CD19-
FITC* structures formed using 12.5 and 25.0 µg/ml of anti-CD19-FITC*
were characterized by saturation of PL intensity due to saturation of
adsorption sites on the surface of ZnO nanorods (Fig. 7). Hence, from
here presented data we can conclude that 6.25 µg/ml is an optimal
concentration of anti-CD19-FITC* for the design of glass/ZnO-NRs/anti-
CD19-FITC* structure, which was supposed to be sensitive to the B-
Fig. 2. Room temperature photoluminescence of bare glass/ZnO-NRs structure
(excitation at 337 nm). Two main emission peaks, near band edge (NBE) and
deep-level (DLE) emissions, are marked in the spectrum with λ=380/510 nm
correspondingly.
Fig. 3. Room temperature photoluminescence of bare ZnO-NRs in concentra-
tion interval of 1–10mg/ml.
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Fig. 4. SEM images of glass/ZnO-NRs modified by 1mg/ml (a); 2.5 mg/ml (b); 5 mg/ml (c); 10mg/ml (d) concentrations of ZnO-NRs after annealing at 300 °C.
Fig. 5. Flow-cytometry based analysis of B-
lymphocytic antigen CD19 in human donor's
lymphocytes where (A) Dot-plot analysis of
PBMCs total population. Abscissa: forward
scatter (cell size); ordinates: side scatter (cell
density); (B, C, D) Flow-cytometry quadrant
analysis of PBMCs: autofluorescence of cells
(B), anti-IgG1-FITC* labeled cells (С), anti-
CD19-FITC* labeled cells. Upper left quadrant:
IgG1- (C) or CD19-possitive cells (D).
Numbering refers to the percentage of B-cells
in PBMCs total population.
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lymphocytes, because this concentration of anti-CD19-FITC* provides
the most efficient coverage of the ZnO-NRs.
The most plausible mechanism of anti-CD19-FITC* adsorption on
ZnO-NRs is based on electrostatic interaction between the surface
charge of ZnO and the charge of proteins (in our case fluorescein-con-
jugated mouse anti-human CD19 monoclonal antibody) and van-der-
Waals interaction [6]. We suppose that the observed changes in ZnO-
NRs photoluminescence can be explained by non-covalent binding of
ZnO-NRs with mouse anti-human CD19-FITC*.
The proteins are bound to ZnO-NRs surface by several functional
groups. In order to prove the formation of bonds between the ZnO-NRs,
deposited on a glass substrate and monoclonal antibody – anti-CD19-
FITC*, the experiments with anti-CD19-FITC* fixation by the paraf-
ormaldehyde (PFA) that cross-link thiol (SH-), amine (NH2-), carboxyl
(COOH-), hydroxyl (OH-) groups of protein molecules were conducted.
Anti-CD19-FITC* were pretreated with 1% paraformaldehyde solution
and dropped on a ZnO-NRs platform. Fig. 8 shows that the NBE emis-
sion of ZnO-NRs has increased after the immobilization of anti-CD19-
FITC* at a concentration of 6.75 µg/ml. After the fixation of anti-CD19-
FITC* with PFA the reduction of PL intensity until values corresponding
the ZnO-NRs with PBS and PFA was observed. Interestingly, that PL
intensity of ZnO-NRs after the paraformaldehyde solution addition did
not changed if compared to values corresponding to that observed for
ZnO-NRs after addition of PBS (Fig. 8). These results support hypothesis
that electron-rich groups, such as SH-, OH-, NH2-, of the ligands (in our
case ligand is anti-CD19-FITC*) improve the PL of ZnO-NRs. Previously,
we have investigated non-specific interaction between surface of ZnO
and biomolecules [15]. The non significant changes of ZnO emission
were observed as result of interaction with non labeled antibodies.
Because the FITC* absorption and emission ranges are out of excitation
and emission of ZnO nanorods, the interaction between FITC* and ZnO,
Fig. 6. Flow cytometry based analysis of B-
lymphocytic antigen CD19 in human B-lym-
phoblastoid cell line IM9 where: (A) Dot-plot
analysis of IM9 cell line. Abscissa: forward
scatter (cell size); ordinates: side scatter (cell
density); (B, C, D) Flow cytometric quadrant
analysis of IM9 cell line: autofluorescence of
cells (B), anti-IgG1-FITC* labeled cells (С),
anti-CD19-FITC* labeled cells. Upper left
quadrant: IgG1- (C) or CD19-possitive cells (D).
Numbering refers to the percentage of B-cells
in IM9 cell line.
Fig. 7. Mean values of PL intensities of glass/ZnO-NRs/anti-CD19-FITC*
structures formed from solution containing 1.25 – 25.0 µg/ml of anti-CD19-
FITC*.
Fig. 8. PL spectra of glass/ZnO-NRs platform modified by anti-CD19-
FITC*(glass/ZnO-NRs/anti-CD19-FITC*): 1 – glass/ZnO-NRs, 2 – glass/ZnO-
NRs/PFA, 3 – glass/ZnO-NRs/PFA/anti-CD19-FITC*, 4 – glass/ZnO-NRs/anti-
CD19-FITC*.
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which was previously reported by Gupta et al. [28], plays the most
important role for the increase of PL. Gupta et al. reported that in-
tegrated intensity of ZnO photoluminescence increases after the mod-
ification ZnO by FITC* [28]. According to Gupta et al., chemical
binding between ZnO and FITC* is formed [28].
3.4. Microstructure and photoluminescence properties of ZnO-NRs after the
modification by cells conjugated with FITC* labeled monoclonal antibodies
Immunophenotyping of donor's peripheral mononuclear cells and
human's B-lymphoblast cell line IM9 for the estimation of CD19 marker
expression on cell surface revealed 4.62% and 95.02%, respectively. To
analyze the possibility of detection of B-lymphocytes using glass/ZnO-
NR platforms the PL spectrum was recorded after the interaction of both
cell lines (IM9+anti-CD19-FITC* and PBMC+anti-CD19-FITC*) con-
jugated with anti-CD19-FITC*.
Fig. 9 shows that NBE emission peak of glass/ZnO-NR platforms
after the treatment by FITC* non-labeled by anti-CD19-FITC* cells: IM9
cell line and PBMC is diffrent from NBE emission peak, which is typical
for ZnO-NRs after PBS addition in the range of 10–15%. However after
the immobilization of PBMC+anti-CD19-FITC* and IM9+anti-CD19-
FITC* cells on the ZnO-NRs platform the PL intensity is increased from
13,700 a.u. (ZnO-NRs with PBS) till 18,300 and 25,000 a.u., respec-
tively (Fig. 9).
Further, the sensitivity of the prepared ZnO-NRs-based platforms
was studied in a wide range of B-lymphocytes concentrations (Figs. 10
and 11). For this B-lymphoblast cells pre-modified with anti-CD19-
FITC* and anti-IgG1-FITC* antibodies were detected by the intensity of
NBE spectra at different concentrations ranging from 10 till 1000 cells
per 1mm2 on the surface of glass/ZnO-NRs platform. Fig. 10A shows
that PL intensity of ZnO-NRs increased by the rise of CD19-positive cell
(or B-lymphocyte) in the investigated sample. However at high IM9 cell
concentrations (500–1000 cells per 1mm2) the intensity of PL spectra
reached steady-state value. The similar tendency of PL intensity in-
crease we have registered after the interaction of cells labeled with anti-
IgG1-FITC* with ZnO-NRs surface (Fig. 10B) that characterizes the non-
specific background signal caused by the anti-CD19-FITC*.
In the Fig. 11 we represent dynamic changes of ZnO-NRs photo-
luminescence after the incubation of human B-lymphoblast cell line
IM9 pre-modified with anti-CD19-FITC* and anti-IgG1-FITC* on the
surface of ZnO-NRs. These results were observed after the subtraction of
PL intensity values of glass/ZnO-NRs structure from values of PL in-
tensity of glass/ZnO-NRs/IM9+anti-CD19-FITC* and glass/ZnO-NRs/
IM9+anti-IgG1-FITC*, respectively. This approach provides the op-
portunity to register the effect, caused by the interaction of the B-cells
labeled with anti-CD19-FITC* and anti-IgG1-FITC* under the adhesion
to ZnO-NRs based platforms. The values of ZnO-NRs PL intensity after
immobilization of cells conjugated with anti-IgG1-FITC* are used as an
initial point for calculation of the net effect in glass/ZnO-NR platform
response. Hence, from Fig. 11 we can conclude that net effect was
averaged from 50% (10 cells per 1mm2) until 200% (500 cells per
1mm2).
Using scanning electron microscopy images of IM9 cell line con-
jugated in vitro with anti-CD19-FITC*monoclonal antibody (IM9+anti-
CD19-FITC*) (Fig. 12A and B) and with anti-IgG1-FITC* polyclonal
antibody (IM9+anti-IgG1-FITC*) in order to perform isotype control
(Fig. 13A and B) after the adhesion on the glass/ZnO-NRs were ob-
tained. It is shown that the anti-CD19-FITC*monoclonal antibody
(Fig. 12B) and anti-IgG1-FITC* used for isotype control (Fig. 13B) are
localized on the IM9 cell line surface as globules that results in the
increase of the surface area of IM9 cell line and area for the adhesion of
cells with ZnO-NRs-based platforms. Thus, we can conclude that the
obtained rise of PL intensity of ZnO-NRs (NBE peak) after the im-
mobilization of FITC*-labeled antibodies and cells (Figs. 7, 9, 10) is a
result of the decrease of negative surface potential [29] and an increase
in Zn-S bond formation on ZnO-NRs-based platforms [30].
Fig. 9. PL spectra of bare ZnO-NRs, modified with cell lines: 1 – glass/ZnO-NRs,
2 – glass/ZnO-NRs/PBMC, 3 – glass/ZnO-NRs/PBMC/anti-CD19-FITC*, 4 –
glass/ZnO-NRs/IM9, 5 – glass/ZnO-NRs/IM9/anti-CD19-FITC*.
Fig. 10. PL spectra of: A) - glass/ZnO-NRs/IM9/anti-CD19-FITC*(1–0 cells,
2–10 cells, 3–100 cells, 4–500 cells, 5–1000 cells); B) - glass/ZnO-NRs/IM9/
anti- IgG1-FITC*(1–0 cells, 2–10 cells, 3–100 cells, 4–500 cells, 5–1000 cells).
Fig. 11. PL intensity ZnO-NRs vs cells concentration: 1 – glass/ZnO-NRs/IM9/
anti-CD19-FITC*, 2 – glass/ZnO-NRs/IM9/anti-IgG1-FITC*.
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3.5. Raman spectroscopy evaluation of glass/ZnO-NRs-based
immunosensing platform before and after the interaction with target cells
Raman scattering was applied to study the chemical bonds that arise
during the immobilization of anti-CD19-FITC* antibodies on the surface
of glass/ZnO-NRs and after interaction with cells. Raman spectra were
registered for unmodified glass/ZnO-NRs, glass/ZnO-NRs modified by
anti-CD19-FITC* (glass/ZnO-NRs/anti-CD19-FITC*) structures and for
IM9 cell line conjugated in vitro with anti-CD19-FITC* and immobilized
on glass/ZnO-NRs platform (glass/ZnO-NRs/IM9+anti-CD19-FITC*).
Raman spectra of ZnO-NRs before and after the functionalization are
shown in Fig. 14. According to [31], Raman peaks of ZnO-NRs, located at
326, 382, 442 and 574 cm-1 correspond to E2 high- E2 low, A1(LO), E2 high
and E1(LO), respectively. Immobilization of anti-CD19-FITC* on ZnO-
NRs surface resulted in 30 cm-1 shift of the peaks at 326 and 442 cm-1
towards lower wave numbers, peak at 382 cm-1 has been quenched, peak
at 574 cm-1 has shifted to 582 cm-1. ZnO-NRs treated by complex IM9
cells with anti-CD19-FITC* resulted to complete the quenching of Raman
peaks attributed to ZnO-NRs. New peaks, in the range of 1250–1750 cm-1
and 2950–3500 cm-1 have been observed, which corresponds to vibra-
tions of amino and carboxyle groups [32,33].
4. Conclusion
This study the applicability of ZnO-nanorod-based immunosensing
platform for the detection cancer cell (B-lymphoblastoid cell line IM9)
has been demonstrated. The photoluminescent spectra of zinc oxide
nanorods exhibit strong near-band-edge (NBE) emission, we have ap-
plied this part of PL spectra for the evaluation of glass/ZnO-NR-based
platforms before and after the immobilization of antibodies and inter-
action with human blood cells.
SEM and PL based investigations revealed that 6,25 µg/ml is an
optimal concentration of anti-CD19-FITC* for the modification of glass/
ZnO-NRs-based substrate in order to design immunosensor. Moreover
we observed that electron-rich groups, such as SH-, OH-, NH2- and
FITC* of anti-CD19-FITC* monoclonal antibody increase the PL of ZnO-
NRs.
Fig. 12. SEM images of IM9 cell line conjugated with anti-CD19-FITC*(IM9+anti-CD19-FITC*) immobilized on the surface of glass/ZnO-NRs structure at 1.00k (A)
and 5.00k (B) magnifications.
Fig. 13. SEM images IM9 cell line conjugated with anti-IgG1-FITC*(IM9+anti-IgG1-FITC*) immobilized on glass/ZnO-NRs at 1.00k (A) and 5.00k (B) magnifica-
tions.
Fig. 14. Raman spectra ZnO-NRs after modification: 1 – glass/ZnO-NRs/, 2 –
glass/ZnO-NRs/anti-CD19-FITC*, 3 – glass/ZnO-NRs/IM9/anti-CD19-FITC*.
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Using flow cytometry we have demonstrated that positive expres-
sion rates of CD19 marker in human B-lymphoblastoid cell line IM9 is
on the average 95% compared with that of donor's lymphocytes where
only 5% of CD19 positive cells were detected. Meanwhile it was shown
that B-lymphoblastoid cells modified with anti-CD19-FITC* bind to
ZnO-NR platforms with high selectivity. It was shown that PL signal of
glass/ZnO-NRs/IM9+anti-CD19-FITC* platform increases by 50–70%
in comparison with the signal which is registered for glass/ZnO-NRs/
PBMC+anti-CD19-FITC* structure. The rise of the ZnO-NRs photo-
luminescence intensity has correlated with CD19 positive cells number
in the investigated populations.
Simultaneously, using SEM and Raman spectroscopy the structural
and electronic properties of formed glass/ZnO-NRs platforms after the
immobilization of B-lymphoblasts labeled with anti-CD19-FITC* and
anti-IgG1-FITC* were investigated. Raman spectroscopy data revealed
that Raman signal is changing after the immobilization of anti-CD19-
FITC* on the ZnO-NRs-based platforms and their interaction with target
cells.
The PL measurements confirmed that the photoluminescence of
ZnO-NRs is useful for the design of devoted immunosensors for the
determination of human В-lymphoblasts at low cell concentrations –
from 10 until 500 cells/(per 1mm2 of ZnO-NRs-based platform).
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